Interview: Cubist's Steven Gilman on succeeding with antibiotics
This article was originally published in Scrip
It's no secret that we urgently need new antibiotics to combat the growing resistance to existing drugs. It's also no secret that commercial incentives to develop new antibiotics are lacking. Big pharma in particular has reduced its R&D in the space over recent years and that's understandable, given the scientific challenges, the limited patent life for medicines, the short duration of antibiotic treatment regimens, drug pricing constraints, regulatory uncertainties and the need to hold new antibiotics in reserve to delay the development of resistance for as long as possible.